NUVB SEC filings, in plain English
Everything Panacea Acquisition Corp has filed with the SEC that we hold — 40 filings, newest first, 5 with a plain-English summary of what changed and why it matters. Every row links to the primary document on EDGAR, so you can check the source rather than trust us.
The feed
live EDGAR captureNew filings appear here within minutes of hitting EDGAR; summaries follow once the pipeline has read them.
What changed: Nuvation Bio Inc. (NYSE: NUVB) furnished a press release reporting second quarter 2026 results. Total revenue was $31.7 million including $23.2 million of net product revenue for IBTROZI (taletrectinib), 25% quarter-over-quarter growth, with approximately 85% of roughly 160 new patient starts being TKI-naïve, about 30% sequential growth in that setting. Why it matters: $661.0 million of liquidity plus $315.6 million raised in July on a 0.75% coupon, with capped calls limiting dilution to a $10.4580 cap, funds the launch without equity issuance at $5.81. The 25% sequential product growth and the 85% TKI-naïve mix matter because first-line patients stay on therapy longer, which is what converts new starts into a durable revenue base.
What changed: The 10-Q filed under Commission file number 001-39351 is that of Nuvation Bio Inc. (NYSE: NUVB) for the quarter ended June 30, 2026, with 351,123,233 shares outstanding as of August 3, 2026. Cash and equivalents rose to $258,604 thousand from $164,086 thousand at December 31, 2025 and marketable securities to $402,352 thousand from $365,125 thousand, taking total current assets to $726,432 thousand and total assets to $744,503 thousand from $594,822 thousand. Accounts receivable rose to $27,826 thousand from $16,076 thousand and inventory to $19,901 thousand from $11,411 thousand. Why it matters: Receivables and inventory both rose about 73% in six months, which is the balance-sheet signature of a commercial launch rather than a development-stage company. The revenue interest financing liability is a claim against future product sales rather than a conventional borrowing, and it appears on both sides of the current line.
What changed: Nuvation Bio Inc., the Panacea Acquisition Corp successor, issued an additional $37.5 million principal amount of 0.75% Convertible Senior Notes due 2032 on July 6, 2026 on the underwriters' full exercise of the over-allotment option granted under the June 25, 2026 underwriting agreement with Jefferies, Citigroup and Cantor Fitzgerald. Total notes sold in the offering were $287.5 million, with estimated net proceeds of approximately $277.6 million after discounts, commissions and expenses. Net proceeds from the greenshoe paid about $2.2 million for additional capped call transactions. Why it matters: Raising $287.5 million at a 0.75% coupon is exceptionally cheap money for a clinical-stage company, and the capped call purchased alongside it raises the effective conversion price so that fewer shares are ultimately issued if the stock rises. For former NUVB holders that combination — near-zero cash interest and reduced conversion dilution — is the best available financing outcome, at the cost of $2.2 million spent on the additional capped calls and a 2032 maturity ranking ahead of the equity.
What changed: Nuvation Bio Inc., successor to Panacea Acquisition Corp, completed a registered public offering on June 30, 2026 of $250.0 million aggregate principal amount of 0.75% convertible senior notes due 2032, with a 30-day underwriter option for a further $37.5 million. Jefferies, Citigroup Global Markets and Cantor Fitzgerald acted as representatives of the underwriters. The notes are general unsecured obligations, pay interest semiannually on January 1 and July 1 from January 1, 2027, and mature on July 1, 2032 unless converted, redeemed or repurchased earlier. Why it matters: This is $250 million of new convertible debt ranking as a general unsecured obligation, with conversion available before April 1, 2032 only on stated conditions — among them the shares trading above 130% of the conversion price on at least five days in the first twenty of a quarter. To permit the issue the company also amended its March 3, 2025 revenue interest financing agreement with a Sagard Healthcare entity.
What changed: Nuvation Bio Inc., the successor to Panacea Acquisition Corp, called its 2026 annual meeting for May 21, 2026 at 11:00 a.m. Eastern Daylight Time by live audio webcast with no in-person attendance, record date March 25, 2026. Nominees Robert B. Bazemore, Jr., Kim Blickenstaff and Robert Mashal, M.D. stand for election to serve until the 2029 annual meeting. On the record date there were 346,685,831 shares of Class A Stock and 1,000,000 shares of Class B Stock issued and outstanding, with no cumulative voting and one vote per share for each class. Why it matters: A 346.7 million Class A count against just 1,000,000 Class B shares means voting power sits overwhelmingly with the public float - unusual for this cohort and a genuine governance advantage for outside holders. The absence of cumulative voting still lets a plurality control every board seat. No trust or redemption right survives from the Panacea SPAC, so the equity depends entirely on the oncology pipeline behind those 346.7 million shares.
In plain English
Redemption deadlinethe last day to hand shares back for cash
Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.
Cash in trust / trust per sharethe cash the company is holding for each public share
Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.
Accession numberthe SEC's unique id for one filing
Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.